We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
Keep Reading →
July 8 - News
Shares of the two largest kidney care companies in the United States, DaVita HealthCare Partners Inc (NYSE:DVA) and Fresenius Medical Care AG & Co.
Keep Reading →
July 8 - News
Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and high dividend yields.
Keep Reading →
July 5 - News
Recently, I enjoyed an article contributed by Adam Feuerstein ("AF article") regarding Antares Pharma Inc (NASDAQ:ATRS) and its transformational product Otrexup.
Keep Reading →
July 5 - News
When it comes to investing for the long term, sometimes companies that are thought of as “stable” or “boring” turn out to be the best thing for your portfolio.
Keep Reading →
July 5 - News
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Keep Reading →
July 5 - News
When you are looking to add a biotech stock to your portfolio, most of the small cap biotech stocks have a small-sized pipeline.
Keep Reading →
July 5 - News
After all of the hype and hoopla over Pfizer Inc.
Keep Reading →
July 3 - News
It's hard to believe, but 2013 is already more than halfway over. This year has been a good one for many pharmaceutical stocks -- at least so far.
Keep Reading →
July 3 - News
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
July 2 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
July 2 - News
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
Keep Reading →
July 2 - News
What’s the worst nightmare of all pharmaceutical companies? Generics. They might as well be the grim reaper in the eyes of the brand-name pharmaceuticals.
Keep Reading →
July 2 - News
Dividend growth investing is a slow and steady process taking place over a long period of time.
Keep Reading →
July 1 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
July 1 - News
Amgen, Inc. (NASDAQ:AMGN) has gone up a lot in share price over the last few years. Amgen, Inc.
Keep Reading →
July 1 - News
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Keep Reading →
July 1 - News
If you owned Johnson & Johnson (NYSE:JNJ) stock at the beginning of 2013, you're sitting atop gains of more than 20% right now.
Keep Reading →
June 28 - News
On June 24, the Food and Drug Administration issued “bioequivalence recommendations” for 15 active ingredients used in prescription medications.
Keep Reading →
June 28 - News
Moreover, there is a rising demand for good healthcare in developing countries in the Asia-Pacific region.
Keep Reading →
June 28 - News
Pfizer Inc. (NYSE:PFE) stock is off to a fine start in 2013.
Keep Reading →
June 28 - News
Niche biotech company Warner Chilcott Plc (NASDAQ:WCRX) has been looking for an exit strategy ever since announcing strategic alternatives back in August 2012.
Keep Reading →
June 27 - News
After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly & Co.
Keep Reading →
June 27 - News
Wall Street's bounce back from last week continues today, with the Dow Jones Industrial Average (Dow Jones Indices:.DJI) looking to continue its recent run of triple-digit moves...
Keep Reading →
June 27 - News
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
June 27 - News
These two ratios provide an indication of how successful a company is at generating profits using shareholders' funds and debt, and they have a strong influence on dividend payments...
Keep Reading →
June 27 - News
Johnson & Johnson (NYSE:JNJ) stands alone as a leader across the major health-care industries.
Keep Reading →
June 27 - News
For investors viewing AbbVie Inc (NYSE:ABBV) as a value play since its spin-off from Abbott Laboratories (NYSE:ABT), it is time to think again.
Keep Reading →
June 26 - News
A director at Deloitte Services LP and co-author of The Three Rules: How Exceptional Companies Think, Michael Raynor joins The Fool to share his findings about what makes a company...
Keep Reading →
June 25 - News
Viagra changed the way below-the-belt jokes were told, and certainly, it empowered a lot of men in ways they couldn't have imagined. Without a doubt, Pfizer Inc.
Keep Reading →
June 25 - News
Medical firm Johnson & Johnson (NYSE:JNJ) recently announced a private-company acquisition that could have major implications for one of the markets in which it operates.
Keep Reading →
June 25 - News
The easiest route would involve the companies with the biggest share price movements.
Keep Reading →
June 25 - News
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Keep Reading →
June 24 - News
I recently read Robert Hagstrom's "Investing: The Last Liberal Art", a tome that has some fascinating insights for any investor. The book is full of wisdom from Charlie Munger...
Keep Reading →
June 24 - News
Cancer is one of the deadliest challenges that humans face today. Different forms of cancer have taken millions of lives all around the world.
Keep Reading →
June 19 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
June 19 - News
When the FTC and the U.S. Supreme Court start breathing down your neck it’s not a pleasant thing, and could become very expensive for certain companies.
Keep Reading →
June 18 - News
It’s not easy being a biotech company.
Keep Reading →
June 18 - News
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Keep Reading →
June 18 - News
Abbott Laboratories (NYSE:ABT) seems to think its stock is cheap enough to justify sinking a substantial amount of its nest egg into the company's stock.
Keep Reading →
June 18 - News
Amgen, Inc. (NASDAQ:AMGN) is the world’s largest independent biotechnology company.
Keep Reading →
June 18 - News
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Keep Reading →
June 17 - Stock Analysis
The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for...
Keep Reading →
June 17 - Stock Analysis
As we're now just days away from the next Federal Reserve meeting, fear, concern, and, most importantly, uncertainty ran rampant this past week on Wall Street, causing the three...
Keep Reading →
June 17 - News
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from...
Keep Reading →
June 17 - News
It was another fear-filled week, as investors were concerned that the Federal Reserve may soon begin taking its foot off the gas.
Keep Reading →
June 17 - News
When we go to the hospital, the last thing on our mind is that something could go wrong or that we could actually become sicker than when we first went in.
Keep Reading →
June 17 - News
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
Keep Reading →
June 17 - News
The markets sure lost yesterday's momentum in a hurry.
Keep Reading →
June 14 - News
